CLINICAL TRIALS PROFILE FOR TREOSULFAN
✉ Email this page to a colleague
All Clinical Trials for TREOSULFAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00129155 ↗ | MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | Unknown status | Hospices Civils de Lyon | Phase 2 | 2005-02-01 | In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell. The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1). |
| NCT00168870 ↗ | Study of Metastatic Ocular Melanoma | Unknown status | Charite University, Berlin, Germany | Phase 2 | 2003-02-01 | This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma. |
| NCT00170690 ↗ | Preference Study With Elderly Patients Recurrent Ovarian Cancer | Completed | North Eastern German Society of Gynaecological Oncology | Phase 3 | 2004-08-01 | Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient) |
| NCT00170690 ↗ | Preference Study With Elderly Patients Recurrent Ovarian Cancer | Completed | North Eastern Germany Society of Gynaecologic Oncology | Phase 3 | 2004-08-01 | Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient) |
| NCT00253513 ↗ | Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Completed | medac GmbH | Phase 1/Phase 2 | 2005-06-01 | RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. |
| NCT00253513 ↗ | Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2005-06-01 | RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. |
| NCT00253513 ↗ | Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Completed | OHSU Knight Cancer Institute | Phase 1/Phase 2 | 2005-06-01 | RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TREOSULFAN
Condition Name
Clinical Trial Locations for TREOSULFAN
Trials by Country
Clinical Trial Progress for TREOSULFAN
Clinical Trial Phase
Clinical Trial Sponsors for TREOSULFAN
Sponsor Name
